ATXI — Avenue Therapeutics, Inc.
$0.28
$-0.03 (-8.29%)
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain.
Market Cap
$922590.00
Forward P/E
-0.1x
52-Week Range
N/A
ATXI Price History
Revenue vs. Net Income
$0
Revenue · FY2023
Annual. Net margin is shown under each year.
Free Cash Flow
-$12.5M
FCF · FY2023
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-1552.9%
ROCE · FY2023
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
6.9x
Assets ÷ liabilities · FY2023
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+384.7%
Dilution · FY2023
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
